Eton Pharmaceuticals, Inc.
ETON Healthcare Drug Manufacturers Specialty & Generic
Eton Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $80.0 million, up 104.9% from fiscal 2024. In the quarter to June 2026, revenue grew 98.6%, EPS grew 520.0%, free cash flow fell 8.78% and total debt fell 7.54%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow ETON
Eton Pharmaceuticals, Inc. (ETON) Beneish M-score
Eton Pharmaceuticals, Inc.'s Beneish M-score for fiscal 2025 is −2.24; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2025 | −2.24 | (0.71) |
| FY2024 | −1.53 | 1.49 |
| FY2023 | −3.02 | 2.51 |
| FY2022 | −5.53 | (496.09) |
| FY2021 | 490.55 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 1.07 | — | 0.98 | |
| Gross margin index | 1.12 | — | 0.59 | |
| Asset quality index | 0.74 | — | 0.30 | |
| Sales growth index | 2.05 | — | 1.83 | |
| Depreciation index | 1.05 | — | 0.12 | |
| SG&A index | 0.77 | — | −0.13 | |
| Total accruals to total assets | (0.16) | — | −0.77 | |
| Leverage index | 1.00 | — | −0.33 | |
| Beneish M-score | Low — no pattern the model associates with manipulation | −2.24 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| HROW Harrow, Inc. compare | −3.0× |
| PCRX Pacira BioSciences, Inc. compare | −2.9× |
| ANIP ANI Pharmaceuticals, Inc. compare | −2.6× |
| XERS Xeris Biopharma Holdings, Inc. compare | −2.6× |
| AMPH Amphastar Pharmaceuticals, Inc. compare | −2.6× |
| PAHC Phibro Animal Health Corporation compare | −2.4× |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −2.3× |
| ETON Eton Pharmaceuticals, Inc. | −2.2× |
| CRON Cronos Group Inc. compare | −2.0× |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI